Macular Vascular Density After Aflibercept or Ranibizumab Treatment for Diabetic Macular Edema
NCT07924072, Phase 4, Completed, Benha University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Macular Vascular Density After Aflibercept or Ranibizumab Treatment for Diabetic Macular Edema | ClinicalTrials.gov |
| NCT number | NCT07924072 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Phase 4 | ClinicalTrials.gov |
| Enrollment | 80 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Benha University | ClinicalTrials.gov |
| Conditions | Diabetic Macular Edema | ClinicalTrials.gov |
| Interventions | Ranibizumab, Aflibercept | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Macular Vascular Density Assessed by Optical Coherence Tomography Angiography | Baseline, 3 months, and 6 months after the first injection | Changes in whole-image and foveal vascular density (%) of the superficial capillary plexus (SCP) and deep capillary plexus (DCP) were assessed using optical coherence tomography angiography (OCTA). Vascular density was measured at baseline, 3 months, and 6 months to evaluate and compare the effects of intravitreal ranibizumab and aflibercept in patients with diabetic macular edema. | ClinicalTrials.gov |
| Secondary | Central Retinal Thickness (CRT) | Baseline, 3 months, and 6 months after the first injection | Central retinal thickness was measured in micrometers (µm) using optical coherence tomography (OCT). Changes from baseline were evaluated at 3 and 6 months to assess anatomical improvement following intravitreal ranibizumab or aflibercept treatment. | ClinicalTrials.gov |
| Secondary | Change in Best-Corrected Visual Acuity (BCVA) | Baseline, 3 months, and 6 months after the first injection | Best-corrected visual acuity was assessed using a Snellen visual acuity chart and converted to logarithm of the minimum angle of resolution (LogMAR) values. Changes from baseline were evaluated at 3 and 6 months to assess functional visual improvement following treatment. | ClinicalTrials.gov |
| Secondary | Change in Intraocular Pressure (IOP) | Baseline, 3 months, and 6 months after the first injection | Intraocular pressure was measured in millimeters of mercury (mmHg) using Goldmann applanation tonometry. Changes in intraocular pressure were evaluated during follow-up to assess ocular safety following intravitreal injections. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)